You are here

Oncology Development Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies365体育足球 that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of January 28, 2020

  • Discovery Projects
  • Phase 1
    14
  • Phase 2
    10
  • Phase 3
    11
  • Registration
    5
  • Total40
 
Compound Name
Indication
Phase
Submission Type
Compound Type
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Metastatic Hormone Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Go to clinical trial
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.) Registration Biosimilar Biosimilar
PF-05280586, a potential biosimilar to Rituxan® /MabThera® (rituximab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
CD20 Antigen Antagonist
Go to clinical trial
Follicular Lymphoma (Biosimilar) (E.U.) Registration Biosimilar Biosimilar
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Registration New Molecular Entity Small Molecule
Braftovi (encorafinib) + Erbitux®(cetuximab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and EGFR inhibitor
2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (PRIORITY REVIEW - U.S., E.U.)
Project advanced
Registration Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Non-Muscle-Invasive Bladder cancer (Biologic)
Project advanced
Phase 3 New Molecular Entity Biologic
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Early Breast Cancer in Adjuvant Setting Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 3 Product Enhancement Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer Phase 2 Product Enhancement Small Molecule
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options